CQS
LCTX icon

Credential Qtrade Securities’s Lineage Cell Therapeutics LCTX Stock Holding History

Credential Qtrade Securities’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,920
Closed -$8.29K – 362
2021
Q2 		$8.29K Hold
2,920
– – ﹤0.01% 315
2021
Q1 		$6.92K Hold
2,920
– – ﹤0.01% 307
2020
Q4 		$5.08K Buy
+2,920
New +$4.08K ﹤0.01% 302

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Credential Qtrade Securities's LCTX Position: Q3 2021 in Review

Credential Qtrade Securities sold out of Lineage Cell Therapeutics (LCTX) in Q3 2021, closing a stake of 2,920 shares — an estimated $8.29K sold.

Credential Qtrade Securities first reported a position in LCTX in Q4 2020 and held it in 3 quarters. The position peaked at $8.29K in Q2 2021. 115 funds tracked by Wall St. Rank hold LCTX as of Q3 2021.

  • Credential Qtrade Securities reported no remaining Lineage Cell Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Credential Qtrade Securities sold 2,920 Lineage Cell Therapeutics shares in Q3 2021, an estimated $8.29K.
  • Credential Qtrade Securities first reported a position in Lineage Cell Therapeutics in Q4 2020 and held it in 3 quarters.
  • Credential Qtrade Securities's Lineage Cell Therapeutics position peaked at $8.29K in Q2 2021.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2021.

Based on Credential Qtrade Securities's 13F filing for Q3 2021, filed 21 Jul 2025.